2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Saturday, December 12, 2026
05:30 p.m. - 07:30 p.m.
MCCNO - Hall F
Technology and Procedures, Assays, Molecular Testing, Omics Technologies, Pathology, Bioinformatics, Computational Biology, Emerging Technologies, Profiling, Treatment Considerations, Combination Therapy, Supportive Care, Biological Therapies, Antibody Therapy, Natural Killer (NK) Cell Therapies, Transplantation, (CAR)-T Cell Therapies, Immunotherapy, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Biological Processes, Apoptosis, Pathogenesis, Genomics, Immune Mechanism, Metabolism, Molecular Biology, Multi-Systemic Interactions, Clinical Practice (Health Services and Quality), Clinical Guidelines, Practice Models, Systems-Based Hematology, Diseases, Bone Marrow Failure Syndromes, Acquired Marrow Failure Syndromes , Genetic Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, Research, Fundamental Science, AML, Translational Research, MDS, MPN, Clinical Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Study Population, Human, Adult, Elderly, Pediatric, Young Adult
PAPER

1702 Single-cell transcriptomic analysis identifies CD44 and LGALS1 as dysregulated RNA-binding proteins in HSPC subpopulations during MPN progression to secondary AML

Miaomiao Zhao, Jian Xu, MD2, Jing He3, Wenjuan He, PhD4, Min Hu5, Min Zhang6
1 Department Of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
2 Department Of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
3 Department Of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
4 Department Of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
5 Department of Pharmacy, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
6 Department Of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China

Background:

Progression of myeloproliferative neoplasms (MPNs) to secondary acute myeloid leukemia (sAML) represents a critical clinical challenge with extremely poor outcomes and limited treatment options. The molecular mechanisms driving HSPC dysregulation during this transition remain incompletely understood. RNA-binding proteins (RBPs) have emerged as key regulators of leukemogenesis; however, their cell-type-specific landscape across HSPC subpopulations during MPN progression to sAML has not been defined.

Methods:

Single-cell RNA-seq data (GSE214914) from CD34+ HSPCs of a healthy donor and an MPN patient across three disease stages (early MF, late MF, and sAML) were analyzed. After quality control, 20,586 cells were clustered into 18 subpopulations. Differential expression (DE) analysis was performed across sequential transitions (normal to earlyMF, earlyMF to lateMF, lateMF to sAML). Expression of 2,141 known RBPs was profiled in HSC and C5 (megakaryocyte-erythrocyte progenitor, MEP) subpopulations. RBP-based sub-clustering identified 4 HSC subclusters and 9 MEP subclusters. Co-expression networks were constructed and functional enrichment analyses performed. Validation was conducted using bulk RNA-seq (GSE154409, n=8 AML vs n=4 controls, FDR≤0.05, FC≥2) and survival analysis via the TARGET database.

Results:

HSPC composition underwent progressive remodeling during MPN-to-sAML transition. MMP (C1) increased from 6.6% to 19.5%, while GMP (C9) declined from 6.5% to 2.0%. MEP subpopulations showed consistent expansion (C12: 0.7% to 5.7%; C15: 0.1% to 2.7%). In the lateMF-to-sAML transition, the C5 (MEP) subpopulation exhibited the most pronounced transcriptomic shift, with 141 upregulated genes enriched in platelet activation and focal adhesion pathways. RBP-focused analysis identified 27 differentially expressed RBPs (DE-RBPs) in HSCs during earlyMF (18 up, 9 down) and 19 DE-RBPs in MEPs during lateMF-to-sAML progression (13 up, 6 down). Co-expression network analysis pinpointed CD44 (HSC) and LGALS1 (MEP) as key dysregulated RBPs, with target genes enriched in apoptosis, unfolded protein response, and platelet activation. In bulk RNA-seq of AML patients versus healthy controls, 3,402 DEGs were identified, including 153 RBPs. Among six RBP candidates intersecting with our single-cell findings, high CD44 expression was associated with favorable overall survival, whereas high LGALS1 expression predicted poor prognosis in an independent AML cohort (TARGET database).

Conclusions:

This single-cell transcriptomic study delineates HSPC heterogeneity and RBP dysregulation during MPN-to-sAML progression. CD44 (HSC) and LGALS1 (MEP) are identified as promising RBPs whose aberrant expression may drive leukemic transformation through apoptosis dysregulation, protein homeostasis disruption, and platelet activation. These RBPs represent potential biomarkers and therapeutic targets for MPN progression and sAML. 

Min Zhang: Mabwell (Shanghai) Bioscience Co., Ltd, Shanghai, China - Research Funding